Unable to sell GMO corn at home, Chinese biotech firm looks to US market

Ab food

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

A Chinese biotech seed firm is aiming to launch the country’s first genetically modified corn products overseas on the home turf of the world’s top agricultural companies, as Beijing’s reticence over GMO food keeps the domestic market off limits.

The plan by Beijing-based Origin Agritech to test its technology in the United States, which has dominated the sector with GMO giants such as Monsanto, is the latest effort by a Chinese firm to enter the global industry.

. . . .

Beijing’s GMO policy has at times appeared inconsistent – billions of dollars have been spent on developing technology it hopes will ensure supplies for its 1.4 billion people, while no major food crops have been approved for cultivation given deep-seated anti-GMO sentiment in the country. Bumper harvests in the past decade have also reduced the urgency for new technologies.

“Consumer attitude is one thing, but the government attitude is even more important,” said Huang Dafang, professor at the Biotechnology Research Institute under the Chinese Academy of Agricultural Sciences. That leaves firms like Origin with few options to earn revenues from GMO products in China, he added.

U.S.-listed Origin has invested more than 300 million yuan ($46.90 million) in biotech since 2005 and, without an opportunity to market its product at home, it now plans to enter the United States in 2016, according to a presentation on the Securities and Exchange Commission website.

. . . .

But getting a foothold in such a highly competitive market will not be easy, experts warn.

Read full, original post: With China’s GMO sector in limbo, local seed firm targets U.S.

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-10-11-at-10.24.21-AM
Viewpoint: RFK Jr.’s new CDC head Erica Schwartz greenlights hepatitis B vaccine study critics call “unethical and designed to cast doubts on its safety”
Personalized-Cancer-mRNA-Vaccine-Vial
Personalized mRNA vaccines are poised to revolutionize cancer treatments. Here are the barriers.
Screenshot-2026-10-05-at-11.57.44-AM
Scaremongering or legitimate safety concerns? The political dogfight over America’s food safety system
ChatGPT-Image-Mar-10-2026-01_39_01-PM
Viewpoint—“Miracle molecule” debunked: Why acemannan supplements don’t work
Screenshot-2026-09-22-at-12.26.15-PM
‘Forever chemical’ concerns: Separating hysteria from reasonable concern in the debate over PFAS danger
Screenshot 2026-10-12 at 12.25
Tearful onions? CRISPR has a solution for that
Eating Nuts Adds up to Longer Life x
For millions with peanut allergies, Nurtured Nuts’ CRISPR gene-edited peanuts could ease the fear of accidental exposure
Deepfake Democracy Media Mosaic
31 states have passed a patchwork of laws to limit election deepfake commercials. They’re not working very well.
Screenshot-2026-10-12-at-10.44.38-AM
Widely condemned as unethical, hepatitis B vaccine study funded by RFK Jr’s CDC gets a final greenlight
Open-Menthol-Cigarette-Pack
How the tobacco industry conspired with conservative activists to kill the Biden administration’s proposed ban on menthol cigarettes 
Screenshot-2026-10-08-at-1.23.28-PM
Countries around the world are rushing to pass teenage social media bans. Could they backfire?
AI-Force-Uniform-Insignia-Close-Up
Trump wants an AI Force like Space Force, but that could make AI’s risks harder to manage
generated-1790707585414
Facts & Fallacies podcast: America's health care system is broken. A doctor explains how to fix it
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.